Current therapies and new developments in NASH

Non-alcoholic steatohepatitis is becoming the most importance etiology for advanced liver disease. The field made important progresses in the last years. The complexity of the pathophysiology of NASH is better understood. Multiple non-invasive criculating and imaging biomarkers have been tested. The importance of lifestyles has been reconised and several drugs are tested in clinical trials. This review adresses the challenges that face health care professionals in the management of NASH patients.

Automated summary

Non-alcoholic steatohepatitis is becoming the most important etiology for advanced liver disease. Significant progress has been made in this field in recent years, with better understanding of the complexity of the pathophysiology of NASH and testing of multiple non-invasive biomarkers. The importance of lifestyles has been recognized and clinical trials of several drugs are underway. This review addresses the challenges faced by healthcare professionals in managing NASH patients.